Seminari di Ematologia Oncologica - Società Italiana di Ematologia

Grigg A, Wolf M, Pfreundschuh M, et al. A phase II
study of enzastaurin, a protein kinase C beta inhibitor,
in patients with relapsed or refractory mantle cell lymphoma.
Ann Oncol. 2008; 19: 247-53.
94. Advani R, Sharman JP, Smith SM, Pollyea DA, Boyd
TE, Grant BW, et al. Effect of Btk inhibitor PCI-32765
monotherapy on responses in patients with relapsed
aggressive NHL: Evidence of antitumor activity from
a phase I study (Abstract). J Clin Oncol. 2010: 8012.
95. Cartron G, Thieblemont C, Solal-Celigny P,
Morschhhauser F, Haioun C, Bouabdallah R, et al.
Promising efficacy with the new anti-CD20 antibody
GA101 in heavily pre-treated NHL patients – first results
from a phase II study in patients with relapsed/refractory
DLBCL and MCL (Abstract). Blood. 2010; 116: 2878.
Linfoma mantellare
96. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler
M, Knop S, et al. Tumor regression in cancer patients
by very low doses of a T cell-engaging antibody.
Science. 2008; 321: 974-7.
97. Viardot A, Goebeler M, Scheele JS, Zugmaier G,
Noppeney R, Knop S, et al. Treatment of patients with
non-hodgkin lymphoma (NHL) with CD19/CD3 bispecific
antibody Blinatumomab (MT103): double-step
dose increase to continuous infusion of 60 µg/m2/d
is tolerable and highly effective (Abstract). Blood. 2010;
116: 2880.
98. Jares P, Colomer D, Campo E. Genetic and molecular
pathogenesis of mantle cell lymphoma: perspectives
for new targeted therapeutics. Nat Rev Cancer.
2007; 7: 750-62.
45